The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Synapse Biomedical sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
Synapse Biomedical Inc (Synapse Biomedical) is a medical device company that manufactures, develops, and markets neurostimulation devices. The company offers NeuRx diaphragm pacing systems and DPS system. Its DPS system is used in the treatment of chronic respiratory insufficiency, diaphragm conditioning in muscular dystrophies, spinal cord injuries, and in respiratory short-term intensive care setting. Synapse Biomedical supplies its products to amyotrophic lateral sclerosis centers. The company has its operations in Brazil, Jordan, the UK, Italy, Australia, Spain, Norway, Russia, France, and the US. Synapse Biomedical is headquartered in Oberlin, Ohio, the US.
The key metrics of Synapse Biomedical related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:
As Synapse Biomedical is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Synapse Biomedical.
For a detailed understanding of the performance of Synapse Biomedical, buy the report here.